Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 51INDUSTRY 48NIH 2NETWORK 2FED 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasm Metastasis 1

Interventions

enzalutamide 4pembrolizumab 3apalutamide 3Docetaxel 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Testosterone 2Prednisone 2Leuprolide 2Cholecalciferol 2Celecoxib 2Androgen Antagonists 2sulforaphane 1relugolix 1olaparib 1nilutamide 1histrelin 1gallium 68 PSMA-11 1copanlisib 1capivasertib 1bicalutamide 1avelumab 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Yoga 1Triptorelin Pamoate 1Tablets 1Simvastatin 1Sildenafil Citrate 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
FED × abiraterone × Genitourinary × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

VA Office of Research and Development

Phase 2 Completed
28 enrolled 10 charts
Genitourinary

Newly Diagnosed Oligometastatic Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡